ALTEOGEN Inc. (KOSDAQ:196170)

Market Cap	21.41T -8.6%
Revenue (ttm)	254.01B +60.7%
Net Income	191.70B +103.3%
EPS	2,719.40 +91.7%
Shares Out	69.63M
PE Ratio	113.08
Forward PE	63.65
Dividend	285.38 (0.10%)
Ex-Dividend Date	Dec 29, 2025

Volume	243,410
Open	303,500
Previous Close	307,500
Day's Range	297,500 - 306,000
52-Week Range	194,615 - 437,692
Beta	0.97
Analysts	Buy
Price Target	372,051.28 (+24.22%)
Earnings Date	Nov 13, 2026

About ALTEOGEN

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the tre...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 172
• Stock Exchange: KOSDAQ
• Ticker Symbol: 196170

Financial Performance

In 2025, ALTEOGEN's revenue was 215.86 billion, an increase of 109.87% compared to the previous year's 102.85 billion. Earnings were 141.67 billion, an increase of 127.57%.

Analyst Summary

According to 6 analysts, the average rating for 196170 stock is "Buy." The 12-month stock price target is ₩372,051, which is an increase of 24.22% from the latest price.

Price Target

₩372,051

(24.22% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 1, 2026

Data Sources Report a data error